Recent work has also indicated that the scaffolding adaptor protein GRB2-associated binding protein 2 is required for BCR-ABL-induced leukemogenesis [55], and that IκB kinase-dependent activation of NF-κB can also contribute to Ph+ leukemias [56], whereas others have used the same model to illustrate that targeting methyltransferases, such as protein arginine methyltransferase 5 (PMRT5), can eliminate LSCs [57], thus identifying additional potential therapeutic targets of interest. This evidence concerns the gene ABL1 and leukemia.